Impact of Rifaximin Therapy on Ischemia/Reperfusion Injury in Liver Transplantation: A Propensity Score-Matched Analysis
| Autor: | Ito, Takahiro, Nakamura, Kojiro, Kageyama, Shoichi, Korayem, Islam M, Hirao, Hirofumi, Kadono, Kentaro, Aziz, Justine, Younan, Stephanie, DiNorcia, Joseph, Agopian, Vatche G, Yersiz, Hasan, Farmer, Douglas G, Busuttil, Ronald W, Kupiec-Weglinski, Jerzy W, Kaldas, Fady M |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Graft Rejection
Adult Male Time Factors Biopsy Clinical Sciences Drug Administration Schedule Rifaximin Oral and gastrointestinal Young Adult Postoperative Complications Liver Function Tests Risk Factors Preoperative Care Humans 2.1 Biological and endogenous factors Aetiology Propensity Score Retrospective Studies Aged Transplantation Liver Disease Graft Survival Evaluation of treatments and therapeutic interventions Organ Transplantation Antibiotic Prophylaxis Middle Aged Allografts Liver Transplantation Gastrointestinal Microbiome Survival Rate Liver Reperfusion Injury 6.1 Pharmaceuticals Reperfusion Female Surgery Digestive Diseases Biomarkers |
| Zdroj: | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, vol 25, iss 12 |
| Popis: | Intestinal microbiota is thought to play an important role in hepatic ischemia/reperfusion injury (IRI) after liver transplantation (LT). Rifaximin, a nonabsorbable antibiotic used to treat encephalopathy, exhibits antibacterial activity within the gut. We report the first study examining the impact of pre-LT rifaximin use on reducing hepatic IRI and inflammatory cell infiltration after LT. This retrospective single-center study included adult LT recipients from January 2013 through June 2016. Patients were divided into 2 groups based on duration of rifaximin use before LT: rifaximin group (≥28 days) and control group (none or |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|